Bms-907351
Non Clear Cell Renal Cell Carcinoma (nccRCC)
Kura Oncology, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Non Clear Cell Renal Cell Carcinoma (nccRCC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus Eisai Inc. | Phase 2 | B |
LENVATINIB Eisai Inc. | Phase 2 | B |
Adagrasib Kura Oncology, Inc. | Phase 1 | CC |
Darlifarnib Kura Oncology, Inc. | Phase 1 | CC |
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →